Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 244 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Etoposide Clear all
Completed Phase 1 Interventional

Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

NCT00000660
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Etoposide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
6
States / cities
San Francisco, California • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 5, 2026, 2:19 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
96
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 2:19 AM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 5, 2026, 2:19 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899
View directory record Official record
Conditions
High-risk Large B-cell Lymphoma (LBCL)
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

NCT00927875
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
BMS-833923, Carboplatin, Etoposide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

NCT03236857
View directory record Official record
Conditions
Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions
chemotherapy, venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 25 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 5, 2026, 2:19 AM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

NCT01169636
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Panobinostat, Ifosfamide, Mesna, Carboplatin, Etoposide, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00369317
View directory record Official record
Conditions
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginase, daunorubicin hydrochloride, cytarabine, thioguanine, etoposide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 4 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
88
States / cities
Phoenix, Arizona • Downey, California • Long Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 3 Interventional

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
topotecan/cisplatin, etoposide/cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

NCT00041327
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, Etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

NCT00003573
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 5, 2026, 2:19 AM EDT
Recruiting Phase 1 Interventional

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

NCT05106296
View directory record Official record
Conditions
Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Interventions
Indoximod, Ibrutinib, Cyclophosphamide, Etoposide, Temozolomide
Drug
Lead sponsor
Theodore S. Johnson
Other
Eligibility
3 Years to 25 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 5, 2026, 2:19 AM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

NCT00020566
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, busulfan, doxorubicin hydrochloride, etoposide, ifosfamide, melphalan, vincristine sulfate, autologous hematopoietic stem cell transplantation, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Leicester
Other
Eligibility
Up to 49 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Early Phase 1 Interventional

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

NCT00314743
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Dexamethasone, Aprepitant
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 5, 2026, 2:19 AM EDT
Recruiting Phase 2 Interventional

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290
View directory record Official record
Conditions
Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
Interventions
Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Etoposide phosphate, Cytarabine, Temozolomide (TMZ), Irinotecan
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
Up to 19 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

NCT00589563
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
Interventions
anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 5, 2026, 2:19 AM EDT
Recruiting Phase 2 Interventional

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT04002947
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
Interventions
DA-EPOCH, Rituximab, CHOP, Acalabrutinib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

NCT02794571
View directory record Official record
Conditions
Advanced/Metastatic Tumors
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 5, 2026, 2:19 AM EDT
Terminated Phase 2 Interventional

Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer

NCT00002478
View directory record Official record
Conditions
Cervical Cancer, Ovarian Cancer
Interventions
etoposide
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
47
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 5, 2026, 2:19 AM EDT
Terminated Phase 2 Interventional Results available

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

NCT01525927
View directory record Official record
Conditions
Oropharyngeal Neoplasms
Interventions
chemotherapy, radiotherapy, Reduced dose radiotherapy
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00054327
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
busulfan, cyclophosphamide, cytarabine, radiation therapy, Etoposide, Stem Cell Transfusion
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00003996
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, chemotherapy, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 5, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

NCT00513162
View directory record Official record
Conditions
Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
Interventions
Valproate, Etoposide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 5, 2026, 2:19 AM EDT